Clinical-stage oncology therapeutics company developing targeted drug combinations for biomarker-defined patient groups with substantial unmet need
Clinical-stage oncology therapeutics company developing targeted drug combinations for biomarker-defined patient groups with substantial unmet need. Its drug discovery platform integrates cancer genomics, biological models and machine learning to identify therapeutic targets and combination treatments.